Trial Profile
A clinical study of single-rising dose of CER 002 in healthy male volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs CER 002 (Primary)
- Indications Atherosclerosis; Cardiovascular disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ABIONYX Pharma; Cerenis Therapeutics
- 29 May 2008 New trial record.
- 15 May 2008 Results have been presented in a Cerenis Therapeutics media release.